Innovating Works

Basilea

Desconocido
Train2Target: An integrated mulTidisciplinary appRoach towards a new generAtIon of aNtibiotics Targeting function... Basilea Pharmaceutica International AG participó en un H2020 H2020-MSCA-ITN-2016 Train2Target is a multidisciplinary European Training Network built to address the challenge of the discovery of alternative antimicrobials....
2016-08-31 - 2020-12-31 | Financiado
IABC PROGRAMME: iABC Programme Basilea Pharmaceutica International AG participó en un FP6 Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10...
2015-08-01 - 2021-12-31 | Financiado
COMBACTE-CARE: Combatting Bacterial Resistance in Europe - Carbapenem Resistance Basilea Pharmaceutica International AG participó en un FP6 Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge!Antibiotic resistance is a global public health concern recent...
2015-03-01 - 2020-02-28 | Financiado
COMBACTE-MAGNET: Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections Basilea Pharmaceutica International AG participó en un FP6 Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of mult...
2015-01-01 - 2021-12-31 | Financiado
ENABLE: European Gram Negative Antibacterial Engine Basilea Pharmaceutica International AG participó en un FP6 The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens...
2014-02-01 - 2020-01-31 | Financiado
TRANSLOCATION: Molecular basis of the outer membrane permeability Basilea Pharmaceutica International AG participó en un FP6 Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and...
2013-01-01 - 2018-06-30 | Financiado
COMBACTE-MAGNET: Combatting Bacterial Resistance in Europe Molecules against Gram Negative Infections Basilea Pharmaceutica International AG participó en un FP7 Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of mult...
Financiado
COMBACTE-CARE: Combatting Bacterial Resistance in Europe Carbapenem Resistance Basilea Pharmaceutica International AG participó en un FP7 Multi-drug resistant Gram-negative bacteria (MDR-GNB): the ultimate challenge! Antibiotic resistance is a global public health concern recen...
Financiado
IABC PROGRAMME: iABC Programme Basilea Pharmaceutica International AG participó en un FP7 Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10...
Financiado
TRANSLOCATION: Molecular basis of the outer membrane permeability Basilea Pharmaceutica International AG participó en un FP7 Overcoming the barriers that the cell envelope and efflux pumps provide to Gram-negative bacteria is a major bottleneck in the discovery and...
Financiado
ENABLE: European Gram Negative Antibacterial Engine Basilea Pharmaceutica International AG participó en un FP7 The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.